Literature DB >> 12213723

Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis.

Sebastian F Schoppmann1, Peter Birner, Johannes Stöckl, Romana Kalt, Robert Ullrich, Carola Caucig, Ernst Kriehuber, Katalin Nagy, Kari Alitalo, Dontscho Kerjaschki.   

Abstract

Formation of lymphatic metastasis is the initial step of generalized spreading of tumor cells and predicts poor clinical prognosis. Lymphatic vessels generally arise within the peritumoral stroma, although the lymphangiopoietic vascular endothelial growth factors (VEGF)-C and -D are produced by tumor cells. In a carefully selected collection of human cervical cancers (stage pT1b1) we demonstrate by quantitative immunohistochemistry and in situ hybridization that density of lymphatic microvessels is significantly increased in peritumoral stroma, and that a subset of stromal cells express large amounts of VEGF-C and VEGF-D. The density of cells producing these vascular growth factors correlates with peritumoral inflammatory stroma reaction, lymphatic microvessel density, and indirectly with peritumoral carcinomatous lymphangiosis and frequency of lymph node metastasis. The VEGF-C- and VEGF-D-producing stroma cells were identified in situ as a subset of activated tumor-associated macrophages (TAMs) by expression of a panel of macrophage-specific markers, including CD68, CD23, and CD14. These TAMs also expressed the VEGF-C- and VEGF-D-specific tyrosine kinase receptor VEGFR-3. As TAMs are derived from monocytes in the circulation, a search in peripheral blood for candidate precursors of VEGFR-3-expressing TAMs revealed a subfraction of CD14-positive, VEGFR-3-expressing monocytes, that, however, failed to express VEGF-C and VEGF-D. Only after in vitro incubation with tumor necrosis factor-alpha, lipopolysaccharide, or VEGF-D did these monocytes start to synthesize VEGF-C de novo. In conclusion VEGF-C-expressing TAMs play a novel role in peritumoral lymphangiogenesis and subsequent dissemination in human cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12213723      PMCID: PMC1867252          DOI: 10.1016/S0002-9440(10)64255-1

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  43 in total

1.  Molecular cloning of a novel vascular endothelial growth factor, VEGF-D.

Authors:  Y Yamada; J Nezu; M Shimane; Y Hirata
Journal:  Genomics       Date:  1997-06-15       Impact factor: 5.736

2.  Proteolytic processing regulates receptor specificity and activity of VEGF-C.

Authors:  V Joukov; T Sorsa; V Kumar; M Jeltsch; L Claesson-Welsh; Y Cao; O Saksela; N Kalkkinen; K Alitalo
Journal:  EMBO J       Date:  1997-07-01       Impact factor: 11.598

3.  Molecular and functional characteristics of dendritic cells generated from highly purified CD14+ peripheral blood monocytes.

Authors:  W F Pickl; O Majdic; P Kohl; J Stöckl; E Riedl; C Scheinecker; C Bello-Fernandez; W Knapp
Journal:  J Immunol       Date:  1996-11-01       Impact factor: 5.422

4.  Prox1 function is required for the development of the murine lymphatic system.

Authors:  J T Wigle; G Oliver
Journal:  Cell       Date:  1999-09-17       Impact factor: 41.582

5.  Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium.

Authors:  S Breiteneder-Geleff; A Soleiman; H Kowalski; R Horvat; G Amann; E Kriehuber; K Diem; W Weninger; E Tschachler; K Alitalo; D Kerjaschki
Journal:  Am J Pathol       Date:  1999-02       Impact factor: 4.307

6.  Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation.

Authors:  U Wartiovaara; P Salven; H Mikkola; R Lassila; J Kaukonen; V Joukov; A Orpana; A Ristimäki; M Heikinheimo; H Joensuu; K Alitalo; A Palotie
Journal:  Thromb Haemost       Date:  1998-07       Impact factor: 5.249

7.  Epitope-specific antibodies to the 43-kD glomerular membrane protein podoplanin cause proteinuria and rapid flattening of podocytes.

Authors:  K Matsui; S Breiteneder-Geleff; D Kerjaschki
Journal:  J Am Soc Nephrol       Date:  1998-11       Impact factor: 10.121

8.  A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases.

Authors:  V Joukov; K Pajusola; A Kaipainen; D Chilov; I Lahtinen; E Kukk; O Saksela; N Kalkkinen; K Alitalo
Journal:  EMBO J       Date:  1996-01-15       Impact factor: 11.598

9.  LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan.

Authors:  S Banerji; J Ni; S X Wang; S Clasper; J Su; R Tammi; M Jones; D G Jackson
Journal:  J Cell Biol       Date:  1999-02-22       Impact factor: 10.539

10.  Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis.

Authors:  T Tsurusaki; S Kanda; H Sakai; H Kanetake; Y Saito; K Alitalo; T Koji
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

View more
  257 in total

1.  Stromal expression of vascular endothelial growth factor C is relevant to predict sentinel lymph node status in melanomas.

Authors:  Elena Gallego; Luis Vicioso; Martina Alvarez; Isabel Hierro; Lidia Pérez-Villa; Alfredo Blanes; Alfredo Matilla
Journal:  Virchows Arch       Date:  2011-01-29       Impact factor: 4.064

2.  Double target for tumor mass destruction.

Authors:  Pipsa Saharinen; Kari Alitalo
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

3.  In vivo imaging of lymphatic vessels in development, wound healing, inflammation, and tumor metastasis.

Authors:  Inés Martínez-Corral; David Olmeda; Rodrigo Diéguez-Hurtado; Tuomas Tammela; Kari Alitalo; Sagrario Ortega
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-02       Impact factor: 11.205

Review 4.  Myeloid cells and lymphangiogenesis.

Authors:  Adrian Zumsteg; Gerhard Christofori
Journal:  Cold Spring Harb Perspect Med       Date:  2012-06       Impact factor: 6.915

5.  Increased lymphatic vessels in patients with encapsulating peritoneal sclerosis.

Authors:  Tatsuhiro Yaginuma; Izumi Yamamoto; Hiroyasu Yamamoto; Jun Mitome; Yudo Tanno; Keitaro Yokoyama; Takenori Hayashi; Tetsuya Kobayashi; Michiaki Watanabe; Yutaka Yamaguchi; Tatsuo Hosoya
Journal:  Perit Dial Int       Date:  2012-06-01       Impact factor: 1.756

6.  Macrophages define dermal lymphatic vessel calibre during development by regulating lymphatic endothelial cell proliferation.

Authors:  Emma J Gordon; Sujata Rao; Jeffrey W Pollard; Stephen L Nutt; Richard A Lang; Natasha L Harvey
Journal:  Development       Date:  2010-11       Impact factor: 6.868

7.  Insulin-like growth factor-1 induces lymphangiogenesis and facilitates lymphatic metastasis in colorectal cancer.

Authors:  Zhen-Jun Li; Xiao-Jiang Ying; Hong-Liang Chen; Ping-Jiang Ye; Zhi-Liang Chen; Gang Li; Hua-Feng Jiang; Jiang Liu; Shu-Zhen Zhou
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

8.  Increase in podoplanin-expressing intestinal lymphatic vessels in inflammatory bowel disease.

Authors:  Silvana Geleff; Sebastian F Schoppmann; Georg Oberhuber
Journal:  Virchows Arch       Date:  2003-01-16       Impact factor: 4.064

9.  Anti-inflammatory macrophages activate invasion in pancreatic adenocarcinoma by increasing the MMP9 and ADAM8 expression.

Authors:  Pauli Puolakkainen; Aino Koski; Sanna Vainionpää; Zhanlong Shen; Heikki Repo; Esko Kemppainen; Harri Mustonen; Hanna Seppänen
Journal:  Med Oncol       Date:  2014-02-14       Impact factor: 3.064

10.  Adrenomedullin gene dosage correlates with tumor and lymph node lymphangiogenesis.

Authors:  Natalie O Karpinich; Daniel O Kechele; Scott T Espenschied; Helen H Willcockson; Yuri Fedoriw; Kathleen M Caron
Journal:  FASEB J       Date:  2012-10-25       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.